Quadruple Therapy More Effective Than Metformin Dose Escalation in Diabetes, Suggests Study
South Korea: Researchers have found in a new study from South Korea that adding a fourth oral antidiabetic drug to an existing triple therapy achieved better glycemic control than simply increasing the metformin dose in patients with type 2 diabetes and elevated A1C levels.
A randomized clinical trial published in Diabetes, Obesity and Metabolism by So Ra Kim and colleagues evaluated whether intensifying treatment with an additional oral agent offers advantages over metformin dose escalation in patients whose diabetes remains inadequately controlled on triple oral therapy.
The 24-week, open-label, multicenter study included adults with type 2 diabetes who had glycated hemoglobin (HbA1c) levels between 7.0% and 9.0% despite receiving a combination of metformin and two other oral agents—either a thiazolidinedione (TZD), sodium–glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase 4 inhibitor (DPP-4i). Participants were randomized to either receive an additional fourth drug from a class not previously used or to undergo metformin dose escalation by up to 500 mg per day.
The researchers reported the following findings:
- A total of 193 patients were analyzed, with 145 in the quadruple therapy group and 48 in the metformin uptitration group.
- At 24 weeks, HbA1c reduction was greater with quadruple therapy (0.70%) compared to metformin dose escalation (0.40%).
- Nearly 70% of patients in the quadruple group achieved HbA1c ≤7.0%, compared to less than 50% in the metformin group.
- Quadruple therapy led to improvement in insulin resistance, which was not observed with metformin uptitration.
- A reduction in albuminuria was noted in the quadruple therapy group, indicating potential renal benefit.
- Both treatment approaches had comparable safety profiles.
- Most adverse events were mild and similar between groups.
- Adding a fourth oral agent did not increase treatment-related risks.
The findings highlight the potential role of oral quadruple therapy as an effective strategy for intensifying diabetes management in patients who do not achieve adequate control with standard triple therapy. Instead of solely increasing the metformin dose, incorporating another agent with a different mechanism of action may provide broader metabolic benefits.
Overall, this study supports a shift toward more individualized and mechanism-based treatment strategies in type 2 diabetes. By demonstrating superior efficacy without compromising safety, quadruple oral therapy may offer a practical and effective alternative for patients requiring further glycemic control before considering injectable therapies.
Reference:
Kim SR, Hong JH, Kim SG, et al. Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial. Diabetes Obes Metab. 2026;28(4):3305-3316. doi:10.1111/dom.70527
Next Story